Evidence map›Paper›PMID 32874829›Full record

ArticleActa pharmaceutica Sinica. B2020

Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity.

Yahui Huang, Shuqiang Chen, Shanchao Wu, Guoqiang Dong, Chunquan Sheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yahui HuangDepartment of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
Shuqiang ChenDepartment of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
Shanchao WuDepartment of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
Guoqiang DongDepartment of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
Chunquan ShengDepartment of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds with therapeutic advantages over single target inhibitors and drug combinations. Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent

Indexed as

Antitumor activityBSA, bovine serum albuminCCK-8, cell counting kit-8CPT, camptothecinDIPEA, N,N-diisopropylethylamineDMF, dimethylformamideDual inhibitorsEto, etoposideEvodiamineHATU, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphateHDAC, histone deacetylaseHistone deacetylaseIP, intraperitoneal injectionOD, optical densityPI, propidium iodideSD, Sprague–DawleySDS, sodium dodecyl sulfateTAE, Tris-acetate-EDTATGI, tumor growth inhibitionTopoisomeraseTOP, topoisomeraseZBG, zinc-binding group

Identifiers

PMID32874829
PMCPMC7452071

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.